04:47 PM EDT, 09/29/2025 (MT Newswires) -- Metsera ( MTSR ) reported positive Phase 2b results for its ultra-long acting GLP-1 candidate MET-097i, demonstrating strong weight loss efficacy and good tolerability, with the data supporting a Phase 3 start later this year.

In one study, MET-097i led to up to 14.1% placebo-adjusted weight loss at 28 weeks, showing no plateau effect, Metsera ( MTSR ) said Monday in a statement.

Other interim results showed minimal gastrointestinal side effects at the highest dose, the company said.

The trials showed strong retention, with only 2.9% dropout in one phase, and Metsera ( MTSR ) finalized the phase 3 dosing, supporting MET-097i as a once-monthly therapy.

The company plans global phase 3 trials for MET-097i in late 2025, while continuing phase 2b studies and advancing related combination, oral, and prodrug programs.